title: Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma.
abstract: CyclinD1/pRb/ppRb is one of the most important pathways regulating the cell cycle, and related with the development of many cancers. However, the co-alteration of CyclinD1/pRb/ppRb in esophageal squamous cell carcinomas is less understood. This study aims to analyze the combined prognostic significance of cyclinD1 (CCND1) DNA amplification and the co-alteration of CCND1/pRb/ppRB in patients with esophageal squamous cell carcinoma. CCND1 DNA amplification and the protein expression of CCND1, pRb, and ppRb on 100 tumor specimens and 11 normal tissues were detected using real-time quantitative reverse transcription polymerase chain reaction and immunohistochemistry, respectively. Their prognosis significance was analyzed by Kaplan-Meier method. We found that 41% of the patients had CCND1 DNA amplification, which had a short survival time compared with the patients without CCND1 amplification (25.63 months vs. not reached, P=0.007). The patients with the co-alternation of CCND1(+) /pRb(-) /ppRb(+) protein expression levels have a poorer overall survival than the others (11.4 vs. 43.4 months, P=0.001). Cox regression analysis showed that the co-alternation of CCND1/pRb/ppRb and CyclinD1 amplification were the two most independent prognosis factors of patients with esophageal cancer. These findings suggested that CCND1 amplification and co-alternation of CCND1(+) /pRb(-) /ppRb(+) may play a crucial role in the prognostic evaluation of patients with esophageal cancer, and the patients with CCND1(+) /pRb(-) /ppRb(+) have the worst prognosis in all the patients. The results also indicated that the patients with CCND1 amplification or co-alternation of CyclinD1(+) /pRb(-) /ppRb(+) might be the preponderant people for therapy targeting the CCND1/pRb/ppRb pathway in the future.
authors.affiliation: Department of Thoracic Surgery of Guangdong General Hospital, China.
authors.forename: M-T
authors.initials: MT
authors.lastname: Wang
authors.forename: G
authors.initials: G
authors.lastname: Chen
authors.forename: S-J
authors.initials: SJ
authors.lastname: An
authors.forename: Z-H
authors.initials: ZH
authors.lastname: Chen
authors.forename: Z-M
authors.initials: ZM
authors.lastname: Huang
authors.forename: P
authors.initials: P
authors.lastname: Xiao
authors.forename: X-S
authors.initials: XS
authors.lastname: Ben
authors.forename: Z
authors.initials: Z
authors.lastname: Xie
authors.forename: S-L
authors.initials: SL
authors.lastname: Chen
authors.forename: D-L
authors.initials: DL
authors.lastname: Luo
authors.forename: J-M
authors.initials: JM
authors.lastname: Tang
authors.forename: J-Y
authors.initials: JY
authors.lastname: Lin
authors.forename: X-C
authors.initials: XC
authors.lastname: Zhang
authors.forename: Y-L
authors.initials: YL
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000032:analysis*; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D019940:Genes, bcl-1 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D016160:Retinoblastoma Protein / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: C530104:CCND1 protein, human; D004273:DNA, Neoplasm; D016160:Retinoblastoma Protein; D019938:Cyclin D1